About Gilmore

Gilmore is President and Chief Executive Officer of Editas Medicine and a member of the Editas Board of Directors. He joined Editas Medicine in June 2022.

Gilmore brings to Editas more than 20 years of experience in genetic medicine, neurobiology, and clinical development. Gilmore also has a track record of driving and leading several of biotech’s most successful clinical programs and achieving marketing approvals for several medicines, including Amondys^®, Vyondys^®, Spinraza^®, Plegridy^®, and Tecfidera^®.

Gilmore most recently served as Executive Vice President of R&D and Chief Medical Officer at Sarepta Therapeutics. During his tenure at Sarepta, he led the R&D leadership team accountable across the value chain from creating and driving discovery, preclinical and clinical development, and global regulatory strategy of its RNA and gene therapeutic portfolio through to Medical Affairs support of the marketed products. Prior to that, Gilmore held several leadership roles at Biogen over a 15-year period, most recently serving as Senior Vice President responsible for all late-stage clinical development. During his tenure at Biogen, Gilmore oversaw development programs for rare disease, gene and cell therapy, neuromuscular disease, pain, multiple sclerosis, acute neurology, movement disorders, and Alzheimer’s disease.

Gilmore currently serves on the Board of Directors at UNITY Biotechnology, Inc., a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, and at Aptinyx, Inc., a biotechnology company developing therapies for the treatment of brain and nervous system disorders.

Gilmore received a Bachelor of Medicine degree from University College Dublin, a Master of Medical Sciences degree from Harvard University and completed his Neurology Residency training at Massachusetts General Hospital. He is licensed to practice medicine in the state of Massachusetts.